FDA-cleared profile

Ventripoint Medical System Plus (VMS+) 3.0

Ventripoint Diagnostics, Ltd. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: VMS+ 3.0 is an adjunct to existing ultrasound imaging systems intended to record, analyze, store, and retrieve digital ultrasound images for computerized three-dimensional image processing. It is indicated where left-ventricle, right-ventricle, left-atrium, and right-atrium volumes and ejection fractions are warranted or desired.

Clinical role
Ultrasound acquisition, image review, measurement, analysis, or release-specific acquisition assistance under professional control.
Images and patients
Ultrasound · Left ventricle, right ventricle, left atrium, and right atrium
Key limitation
Keep in mind: The exact indication is an adjunct workflow for the four named cardiac chambers and related volume or ejection-fraction analysis; clinical interpretation remains with qualified professionals.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: VMS+ 3.0 is an adjunct to existing ultrasound imaging systems intended to record, analyze, store, and retrieve digital ultrasound images for computerized three-dimensional image processing. It is indicated where left-ventricle, right-ventricle, left-atrium, and right-atrium volumes and ejection fractions are warranted or desired.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Left ventricle, right ventricle, left atrium, and right atrium Input: Supported ultrasound images, fluid-flow data, raw data, probes, and compatible ultrasound-system inputs.
  • Who uses it?Intended users: Qualified physicians, sonographers, and other trained healthcare professionals.
  • What does the software produce?Output: Ultrasound images, measurements, calculations, annotations, quality guidance, and reports for professional review.
  • What is its most important limitation?Key limitation: The exact indication is an adjunct workflow for the four named cardiac chambers and related volume or ejection-fraction analysis; clinical interpretation remains with qualified professionals.

Clinical takeaway. Clinical role: VMS+ 3.0 is an adjunct to existing ultrasound imaging systems intended to record, analyze, store, and retrieve digital ultrasound images for computerized three-dimensional image processing. It is indicated where left-ventricle, right-ventricle, left-atrium, and right-atrium volumes and ejection fractions are warranted or desired.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing: biocompatibility testing of patient-contacting components (ISO 10993-1), electrical safety and EMC testing (IEC 60601-1 and IEC 60601-1-2), software verification and validation, and a performance bench study in which predefined acceptance criteria were met and volume measurements were equivalent in accuracy to volumes obtained using the legally marketed VMS+. It states no clinical tests were conducted to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
VMS+ 3.0 is an adjunct to existing ultrasound imaging systems intended to record, analyze, store, and retrieve digital ultrasound images for computerized three-dimensional image processing. It is indicated where left-ventricle, right-ventricle, left-atrium, and right-atrium volumes and ejection fractions are warranted or desired.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Ultrasound acquisition, image review, measurement, analysis, or release-specific acquisition assistance under professional control.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported ultrasound images, fluid-flow data, raw data, probes, and compatible ultrasound-system inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Ultrasound images, measurements, calculations, annotations, quality guidance, and reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical ultrasound settings within the labeled applications.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified physicians, sonographers, and other trained healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The exact indication is an adjunct workflow for the four named cardiac chambers and related volume or ejection-fraction analysis; clinical interpretation remains with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical testing: biocompatibility testing of patient-contacting components (ISO 10993-1), electrical safety and EMC testing (IEC 60601-1 and IEC 60601-1-2), software verification and validation, and a performance bench study in which predefined acceptance criteria were met and volume measurements were equivalent in accuracy to volumes obtained using the legally marketed VMS+. It states no clinical tests were conducted to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Biocompatibility testing was conducted on patient contacting components of the VMS+ 3.0 device, including evaluation tests for cytotoxicity, sensitization, and irritation of intracutaneous reactivity. The components comply with the ISO 10993-1 standard." … "Electrical safety and EMC testing were conducted on the VMS+ 3.0 device. The system complies with the IEC 60601-1 standard for safety and essential performance and IEC 60601-1-2 standard for electromagnetic compatibility.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing: biocompatibility testing of patient-contacting components (ISO 10993-1), electrical safety and EMC testing (IEC 60601-1 and IEC 60601-1-2), software verification and validation, and a performance bench study in which predefined acceptance criteria were met and volume measurements were equivalent in accuracy to volumes obtained using the legally marketed VMS+. It states no clinical tests were conducted to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Biocompatibility testing was conducted on patient contacting components of the VMS+ 3.0 device, including evaluation tests for cytotoxicity, sensitization, and irritation of intracutaneous reactivity. The components comply with the ISO 10993-1 standard." … "Electrical safety and EMC testing were conducted on the VMS+ 3.0 device. The system complies with the IEC 60601-1 standard for safety and essential performance and IEC 60601-1-2 standard for electromagnetic compatibility.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K191493 FDA decision evidence package for Ventripoint Medical System Plus (VMS+) 3.0

  • DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
  • PopulationLeft ventricle, right ventricle, left atrium, and right atrium
  • Scopeexact submission
  • Tested versionVentripoint Medical System Plus (VMS+) 3.0 configuration described in K191493
  • IndependenceSponsor or vendor study

K191493

FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K191493 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported ultrasound images, fluid-flow data, raw data, probes, and compatible ultrasound-system inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K191493: Ventripoint Medical System Plus (VMS+) 3.0

  2. Routing

    Source context, not route validation: The exact FDA package describes recording ultrasound image sequences from the secondary video output of the 2D ultrasound machine, original VMS+ and DICOM image data formats, and users sending to and retrieving from PACS. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Record the ultrasound image sequences from the secondary video output of the 2D ultrasound machine" … "Original VMS+ and DICOM image data formats". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K191493: Ventripoint Medical System Plus (VMS+) 3.0

  3. AI processing

    Source context, not route validation: The exact FDA package describes knowledge-based reconstruction located locally on the system, console and workstation software, and a medical grade computer mounted to a variable height roll stand. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Knowledge-based reconstruction located locally on the system whereas for the predicate" … "Console (system) and Workstation (standalone) software". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K191493: Ventripoint Medical System Plus (VMS+) 3.0

  4. Returned objects

    Source context, not route validation: Ultrasound images, measurements, calculations, annotations, quality guidance, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K191493: Ventripoint Medical System Plus (VMS+) 3.0

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images, measurements, calculations, annotations, quality guidance, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K191493: Ventripoint Medical System Plus (VMS+) 3.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes knowledge-based reconstruction located locally on the system, console and workstation software, and a medical grade computer mounted to a variable height roll stand. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Knowledge-based reconstruction located locally on the system whereas for the predicate" … "Console (system) and Workstation (standalone) software". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes recording ultrasound image sequences from the secondary video output of the 2D ultrasound machine, original VMS+ and DICOM image data formats, and users sending to and retrieving from PACS. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Record the ultrasound image sequences from the secondary video output of the 2D ultrasound machine" … "Original VMS+ and DICOM image data formats". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Training
Only qualified physicians, sonographers, and other trained healthcare professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K191493 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact indication is an adjunct workflow for the four named cardiac chambers and related volume or ejection-fraction analysis; clinical interpretation remains with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K191493 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact indication is an adjunct workflow for the four named cardiac chambers and related volume or ejection-fraction analysis; clinical interpretation remains with qualified professionals.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

exact submission · checked 2026-09-04

No exact-product price or reimbursement determination was promoted.

Lifecycle monitoring

Monitor K191493 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact indication is an adjunct workflow for the four named cardiac chambers and related volume or ejection-fraction analysis; clinical interpretation remains with qualified professionals.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K191493
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Left ventricle, right ventricle, left atrium, and right atrium
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-10-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

5 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K191493: Ventripoint Medical System Plus (VMS+) 3.0

    U.S. Food and Drug Administration - Published 2019-10-16 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K191493 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241222

Ventripoint Medical System Plus (VMS+) 4.0

Ventripoint Diagnostics Ltd.

Authorized purpose: Ventripoint VMS+ 4.0 is an adjunct to an existing ultrasound system that records, analyzes, stores, and retrieves digital ultrasound images for computerized three-dimensional analysis where cardiac-chamber volumes or ejection fractions are warranted or desired.

Modality
Ultrasound
Anatomy
Left ventricle, right ventricle, left atrium, and right atrium
Decision
2025-02-26
FDA-cleared K173810

Ventripoint Medical System Plus (VMS+)

Ventripoint Diagnostics, Ltd.

Authorized purpose: VMS+ is an adjunct to existing ultrasound imaging systems intended to record, analyze, store, and retrieve digital ultrasound images for computerized three-dimensional image processing. It is indicated where left-ventricle, right-ventricle, left-atrium, and right-atrium volumes and ejection fractions are warranted or desired.

Modality
Ultrasound
Anatomy
Left ventricle, right ventricle, left atrium, and right atrium
Decision
2018-05-14
FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260190

ARTHUR

ROPCA ApS

Authorized purpose: Supervised automatic ultrasound image acquisition of hand and wrist joints in adults being investigated or monitored for musculoskeletal disease.

Modality
Ultrasound
Anatomy
Hand/Wrist
Decision
2026-06-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history